Alumis Shares Surge 95% on Successful Phase 3 Results for Envudeucitinib, a TYK2 Inhibitor Licensed from Haisco

▎Armstrong

On January 6, 2026, Alumis announced the Phase III clinical data of Envudeucitinib, a next-generation TYK2 inhibitor for the treatment of plaque psoriasis. Both Phase III trials met all primary and secondary endpoints.

Affected by this news, Alumis' stock price surged 95% on the same day, with a current market value of 1.7 billion US dollars.

Alumis was founded in 2021, incubated by Forsite Labs, with its core pipeline TYK2 inhibitor Envudeucitinib originating from Haisco.In March 2021, Haisco transferred the patents and rights of its in-development TYK2 inhibitor to FL2021-001 (the predecessor of Alumis) for an upfront payment of $60 million and a potential milestone transaction of $120 million.

Envudeucitinib is a TYK2 inhibitor with differentiated advantages, reflected in its selectivity, optimized molecular properties/pharmacokinetics, maximized target inhibition effect, and better tolerability, among others.

Phase III Clinical Trial Protocol is as follows.

Both Phase III clinical trials met primary and secondary endpoints, with PASI 75 at 74%, sPGA 0/1 at 59% at 16 weeks of treatment, PASI 90 at 65%, and PASI 100 exceeding 40% at 24 weeks.

The efficacy data of Envudeucitinib is comparable to Johnson & Johnson's IL-23 cyclic peptide inhibitor Icotrokinra and superior to the previous generation TYK2 inhibitor Sotyktu (both non-head-to-head comparisons).

Summary

This next-generation TYK2 inhibitor from a Chinese pharmaceutical company has completed Proof of Concept (POC) in Phase III clinical trials, demonstrating significantly superior efficacy compared to the previous generation of TYK2 inhibitors. Its efficacy data is comparable to Johnson & Johnson's IL-23R cyclic peptide inhibitor, Icotrokinra, positioning it to capture a significant share of the $180 billion market opportunity.